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ABSTRACT
Introduction: A majority of patients with
diabetes do not have levels of glycated
hemoglobin (HbA1c) and low-density
lipoprotein cholesterol (LDL-C) under control,
either individually or in combination. The
objective was to assess the clinical benefits and
patient characteristics associated with dual-goal
achievement [HbA1c\7% (53 mmol/mol) and
LDL-C \100 mg/dL] versus only LDL-C goal
achievement in adults with newly diagnosed
type 2 diabetes.
Methods: Newly diagnosed patients with C2
measures of LDL-C and HbA1c were identified
in the South Central Veterans Affairs Health
Care Network (01/2004–06/2010). The index
date was the first HbA1c assessment within
3 months of the first type 2 diabetes diagnosis.
Multivariate Cox proportional hazards models
were used to assess the association between
time-varying goal achievement and post-index
microvascular and cardiovascular
complications. Patient characteristics
associated with dual-goal achievement in the
7–12 months post-index were identified using a
logistic regression.
Results: The sample included 16,829 patients.
Compared with LDL-C goal achievement,
dual-goal achievement was associated with
lower risk of microvascular complications
[hazard ratio (95% confidence interval): 0.69
(0.63, 0.76)]. Other outcomes did not differ
between those two groups. Characteristics
associated with dual-goal achievement (44.2%
of patients) include prior dual-goal achievement,
older age, and use of lipid-lowering drugs.
Conclusion: Dual-goal achievement in newly
diagnosed type 2 diabetes is associated with a
lower risk of microvascular complications
versus only LDL-C goal achievement.
Although dual-goal achievement rates are
suboptimal, early and regular intervention will
increase its likelihood.
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INTRODUCTION
The American Diabetes Association has
recommended that the levels of glycated
hemoglobin (HbA1c) and low-density
lipoprotein cholesterol (LDL-C) in patients
with type 2 diabetes be maintained at \7%
(53 mmol/mol) and \100 mg/dL, respectively
[1]; however, a majority of patients with
diabetes do not have these parameters under
control, either individually or in combination
[2].
HbA1c control has been shown to be
associated with a reduced risk of microvascular
complications in the general population of
patients with diabetes [3–5] but the evidence is
mixed with regards to cardiovascular benefits.
Some studies have observed cardiovascular
benefits of HbA1c control in relatively less
severe patients with diabetes [6–8] or those
newly diagnosed with or screened for diabetes
[8–10]; however, a recent study on the impact of
early use of insulin treatment to normalize
glucose levels found no difference in
cardiovascular benefits compared with
standard treatment [11]. In addition,
cardiovascular benefits of LDL-C control in
diabetes have been well documented [12–16].
An intensive, multifactorial intervention
approach in type 2 diabetes patients, designed
to simultaneously target HbA1c, cholesterol
levels, and other risk factors, has been shown
to significantly reduce the risk of cardiovascular
morbidity and mortality, microvascular
complications, and rates of cardiovascular
surgery [17, 18].
The benefits of achieving both HbA1c and
LDL-C goals, compared with achieving just one,
have not been quantified among newly
diagnosed type 2 diabetes patients.
Cardiovascular disease is the most frequent
cause of death in patients with diabetes [19].
While some studies suggest that tight glycemic
control reduces cardiovascular risk in patients
who are newly diagnosed with diabetes [9], it is
unclear whether achieving the HbA1c goal in
addition to the LDL-C goal will have additional
cardiovascular benefits. The primary objective
of this study was to compare the clinical
benefits of dual-goal achievement versus
achievement of the LDL-C goal only in
patients with newly diagnosed type 2 diabetes.
Additional comparisons included dual-goal
achievement versus HbA1c goal achievement
and no-goal achievement, only LDL-C goal
versus no-goal achievement, and only HbA1c
goal versus no goal achievement. Furthermore,
this study sought to better understand dual-goal
achievement status and identify patient




Electronic medical records from the South
Central Veterans Affairs Health Care Network,
Veterans Integrated Service Network (VISN) 16
(http://www.visn16.va.gov/) were used in this
retrospective observational study. The VISN 16
data warehouse is an integrated, de-identified,
individual-level database that includes records
for more than 445,000 veterans from 10 medical
centers and 40 outpatient clinics in the South
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Central Region of the United States (i.e., Okla-
homa, Arkansas, Louisiana, Mississippi, and
parts of Texas, Missouri, Alabama, and Florida).
The database contains information regarding
demographics, vital signs, laboratory results,
diagnoses and procedures, inpatient and out-
patient services (e.g., admission date, length of
stay, emergency room visits), drug prescrip-
tions, and database enrollment history. All data
comply with the Health Insurance Portability
and Accountability Act (HIPAA). This study was
approved by the Institute Review Board
including a waiver of informed consent and
HIPPA authorization and Research and Devel-
opment Committee of the Southeast Louisiana
Veterans Heath Care System. This article does
not contain any studies with human or animal
subjects performed by any of the authors.
Sample Selection
To identify patients who were recently
diagnosed with type 2 diabetes mellitus,
patients were required to have C2 diagnoses of
type 2 diabetes mellitus between January 1,
2004 and June 30, 2010, but no such diagnosis
for at least 1 year from the start of their
enrollment in the database (Fig. 1). Patients
with more than 1 diagnosis of type 1 diabetes
mellitus were excluded. During the 3-month
period surrounding the first type 2 diabetes
diagnosis, all patients were required to have at
least one measurement of HbA1c and LDL-C
within 30 days of each other; the date of the
earliest HbA1c measurement in this period was
defined as the index date. Patients were required
to be C18 years old at the time of the index
date, be continuously enrolled for at least
12 months, and have C1 measurement of both
HbA1c and LDL-C in the 7- to 12-month period
after the index date. Patients were excluded if
they had taken antidiabetic drugs (oral
antidiabetic drugs or insulin) or had a
measurement of HbA1c C7.0% (53 mmol/mol)
prior to the first diagnosis of type 2 diabetes
mellitus or the index date, whichever was
earlier.
Data Preparation
Longitudinal data were analyzed according to
6-month cycles, starting from the index date.
Average HbA1c and LDL-C levels were estimated
for each cycle using the area under the curve
method [20, 21]. For each cycle, the following
estimated averages were used to group patients
into one of four goal achievement categories:
dual-goal [HbA1c \7% (53 mmol/mol) and
LDL-C\100 mg/dL], HbA1c only [HbA1c\7%
(53 mmol/mol) and LDL-C C100 mg/dL], LDL-C
only [LDL-C \100 mg/dL and HbA1c C7%
(53 mmol/mol)], or neither goal [HbA1c C7%
(53 mmol/mol) and LDL-C C100 mg/dL].
Patient Characteristics
Patient characteristics during the first 6-month
cycle were summarized for the overall sample as
well as stratified by goal achievement status.
Demographic information included age at
index date, gender, race, body mass index
(BMI), and year of index date. The history of
diabetes-related complications [microvascular
(diabetic retinopathy, neuropathy, or
nephropathy), macrovascular (coronary artery
disease, cerebrovascular disease, peripheral
vascular disease, or atherosclerosis), and other
complications such as infection, ocular
problems, etc.], comorbidities, and surgical
procedures were identified and summarized as
of the first cycle using International
Classification of Diseases, Clinical
Modification, Version 9 (ICD-9-CM) codes.
Diabetic medications used by patients during
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the first cycle were categorized by drug
therapeutic class. Healthcare resource
utilization during the first cycle was
categorized by inpatient, outpatient, and
emergency room (ER) visits. Differences in
characteristics between the four patient groups
according to goal achievement status were
assessed using the analysis of variance method
for continuous variables and Chi-squared tests
for categorical variables.
Fig. 1 Sample selection for patients with newly diagnosed type 2 diabetes. Asterisks the date of the earliest HbA1c
measurement was considered the index date. HbA1c glycated hemoglobin A1c, LDL-C low-density lipoprotein cholesterol
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Clinical Outcomes
Clinical outcomes were selected a priori and
included the following: (a) a composite
cardiovascular-related endpoint
[cerebrovascular disease (stroke), acute
myocardial infarction (MI), or cardiovascular
death (defined by a diagnosis of coronary artery
disease or cerebrovascular disease on the day of
death)], (b) acute coronary syndromes (acute MI
or unstable angina), (c) a composite endpoint
for microvascular complications, and
(d) cardiovascular surgical procedures
(coronary artery bypass graft or percutaneous
coronary intervention) (Supplementary
Appendix 1).
For each specific clinical event analyzed,
patients were excluded from the analysis if the
event occurred before the end of the first cycle,
and patients were followed from the start of the
second cycle until the first event, death, or end
of the data. Cox proportional hazards regression
models were used for both descriptive and
multivariate analyses. In the descriptive
analysis, Cox proportional hazards regression
models with time-varying goal achievement
status were used to estimate the proportion of
patients who did not experience specific clinical
events over time. Furthermore, Cox
proportional hazards models were expanded in
the multivariate analysis to adjust for potential
confounding factors: demographics, BMI, and
index year as of the index date, cumulative
diabetes-related comorbidity/complication
history, resource utilization, and medication
use. Goal achievement status and confounding
factors were measured during a given cycle
while the clinical event was measured at the
following cycle. The risk of each clinical event
by goal achievement status was quantified using
adjusted hazard ratios (HRs) with 95%
confidence intervals (95% CIs).
Characteristics Associated with Dual-Goal
Achievement
To identify characteristics associated with
dual-goal achievement 7–12 months after the
index date, a logistic regression model was used
to assess the effects of individual factors. These
include demographics, dual-goal achievement
within 6 months following the index date, and
complications and comorbidities, diabetic
medication use, surgical procedures, resource
utilization (i.e., outpatient, inpatient, and ER
visits), the Charlson Comorbidity Index (CCI, a
validated measure of the overall health status)
[22] within the 1-year period surrounding the
index date (i.e., 6 months before and 6 months
after the index date). The likelihood of
achieving both goals relative to not achieving
both goals was quantified using adjusted odds
ratios (ORs) with 95% CIs. SAS software version
9.2 (Cary, NC, USA) was used to conduct
statistical analyses, and a two-tailed a level of




A total of 16,829 newly diagnosed patients
were included in the analysis (Fig. 1). Patient
characteristics for the overall population are
shown in Table 1. As of the index date, most
patients were over 55 years (80.8%; mean age
63.3 years), male (96.8%), and white (67.0%),
with a mean BMI of 31.8 kg/m2. Patients had a
history of several diabetes-related
complications and comorbidities including
hypertension (79.3%), hyperlipidemia
(72.9%), depression (39.5%), microvascular
complications (19.1%), macrovascular
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complications (38.4%), infection (13.0%), and
ocular problems (30.1%). The percentages of
patients who had undergone lower extremity
amputation, coronary artery bypass graft, or
percutaneous coronary intervention were 0.2,
0.5, and 1.4%, respectively. The majority of
patients were taking oral antidiabetic (52.8%),
antihypertensive (67.9%), and lipid-lowering
drugs (69.4%), while 10.2% of the patients
received insulin during the first 6 months after
index date. The majority of the patients had an
outpatient visit (98.6%) during the first
6 months following the index date, but only
3.8% of the patients had an ER visit; 10.1%
had an inpatient visit during the same period.
During the first 6-month cycle, 39.0% of
patients achieved both goals (dual-goal
achievers), while 14.5% achieved only the
LDL-C goal (LDL-C achievers), 32.2% achieved
only the HbA1c goal (HbA1c achievers), and
14.4% did not achieve either goal (no-goal
achievers) (Table 1). Compared with LDL-C
achievers, HbA1c achievers, and no-goal
achievers, dual-goal achievers were
significantly older (66.2 years vs. 61.8, 62.5,
and 58.7 for LDL-C, HbA1c, and no-goal
achievers, respectively; all P\.001) and more
likely to be white (70.5% vs. 66.7%, 65.8%, and
60.1%; all P\.001). History of depression was
the lowest (34.7% vs. 39.4%, 43.4%, and 43.5%
for LDL-C, HbA1c, and no-goal achievers,
respectively; all P\.001) but history of
macrovascular complications (46.6% vs.
42.9%, 31.0%, and 27.9%; all P\.001) and
hypertension (82.5% vs. 79.0%, 77.1%, and
75.9%; all P\.001) was the highest for
dual-goal achievers compared with other
patient groups. History of microvascular
complications was lower for dual-goal
achievers than LDL-C goal achievers (18.1%
vs. 23.1%; P\.001), but similar between
dual-goal achievers and HbA1c goal achievers
(18.1% vs. 17.3%; P = .245).
Clinical Outcomes
The median duration of follow-up time was
3.7 years. Most patients were free of the
composite cardiovascular endpoint (96.4, 96.3,
96.6, and 95.9% for dual-goal, LDL-C, HbA1c,
and no-goal achievers, respectively), Acute
Coronary Syndrome (ACS) (98.7, 98.2, 98.8,
and 98.0%), or microvascular complications
(89.8, 83.5, 89.7, and 84.6%) during the first
year. After 3 years of follow-up, a large majority
of patients remained free of the composite
cardiovascular endpoint (91.2, 91.0, 91.6, and
90.0% for dual-goal, LDL-C, HbA1c, and
no-goal achievers, respectively), ACS (96.5,
95.2, 96.9, and 94.7%) or microvascular
complications (77.0, 64.6, 76.9, and 66.6%).
After adjusting for potential confounding
factors, the Cox proportional hazards
regressions revealed that newly diagnosed
diabetes patients who achieved both goals
were associated with a lower risk of
microvascular complications than patients
who achieved only the LDL-C goal or those
who did not achieve either goal. In particular,
dual-goal achievement was associated with a
lower risk of microvascular complications
compared with only LDL-C goal achievers
[adjusted HR (95% CI): 0.69 (0.63, 0.76)].
Analyses of all other diabetes-related
complications and surgical procedures revealed
no other statistically significant benefits for
dual-goal achievers relative to single-goal
achievers. Compared with no-goal achievers,
dual-goal achievers had a significantly
decreased risk of experiencing the composite
cardiovascular-related endpoint [0.74 (0.62,
0.87)], acute coronary syndromes [0.69 (0.54,
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0.88)], microvascular complications [0.70 (0.63,
0.78)], and coronary artery bypass grafting [0.40
(0.23, 0.68)] (Fig. 2).
Compared with no-goal achievers, both
groups of single-goal achievers had a
significantly lower risk of experiencing
composite cardiovascular endpoint [LDL goal
achievers: 0.76 (0.71, 0.81); HbA1c goal
achievers: 0.80 (0.74, 0.87)], acute coronary
syndrome [LDL goal achievers: 0.76 (0.67,
0.86); HbA1c goal achievers: 0.66 (0.60, 0.72)],
and coronary artery bypass grafting [LDL goal
achievers: 0.63 (0.45, 0.88); HbA1c goal
achievers: 0.59 (0.44, 0.80)]. HbA1c achievers
had a lower risk of experiencing microvascular
complications [0.73 (0.71, 0.74)], and
undergoing percutaneous coronary
intervention [0.66 (0.53, 0.82)] relative to
no-goal achievers.
Characteristics Associated with Dual-Goal
Achievement
Out of 16,829 patients, 7432 (44.2%) achieved
dual-goal status while 9397 (55.8%) were
non-dual-goal achievers in the 7–12 months
following the index date. The descriptive
statistics of characteristics of these patients are
summarized in Supplementary Appendix 2. The
logistic regression reveals that patient
characteristics associated with an increased
likelihood of dual-goal achievement included
dual-goal achievement during 0–6 months
following the index date [adjusted OR (95%
CI): 16.19 (14.92, 17.58)], a diagnosis of
ketoacidosis (without coma) and
hyperosmolarity [2.20 (1.18, 3.94)], the use of
lipid-lowering drugs [1.53 (1.39, 1.69)], CCI
scores between 1–3 and C3 [compared with
Fig. 2 Risk of experiencing diabetes-related complications
and surgeries in patients with newly diagnosed type 2
diabetes. Dual: patients achieving both LDL-C and HbA1c
goals; HbA1c: patients achieving only the HbA1c goal;
LDL-C: patients achieving only the LDL-C goal; none:
patients achieving neither goal (please see text for details).
CI conﬁdence interval, HbA1c glycated hemoglobin A1c,
LDL-C low-density lipoprotein cholesterol
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CCI = 0; 1.15 (1.03, 1.29) and 1.40 (1.08, 1.81),
respectively], index years of 2007 [1.16 (1.01,
1.33)], 2008 [1.19 (1.04, 1.37)], or 2009 [1.21
(1.03, 1.42)] relative to an index year of 2004,
and age [1.02 (1.01, 1.02)]. Conversely, insulin
use [0. 70 (0.61, 0.81)] and a diagnosis of
retinopathy [0.67 (0.55, 0.82)], neuropathy
[0.85 (0.76, 0.97)], or congestive heart failure
[0.84 (0.70, 0.99)] were associated with a
significantly decreased likelihood of dual-goal
achievement (Table 2).
DISCUSSION
The results from this study show that the
achievement of both HbA1c and LDL-C goals
in patients with newly diagnosed type 2
diabetes is associated with an additional
reduction of microvascular complication rates,
compared with achievement of the LDL-C goal
alone. The benefit of HbA1c goal has a so-called
‘‘glycemic legacy’’ beyond a finite period of
intensive management, as shown in 10-year
follow-up of the UKPDS study
(ClinicalTrials.gov # NCT01099865) [9, 23]. In
addition, this study found that dual- and
single-goal achievements are both generally
superior to not achieving either goal, and
result in a lower risk of cardiovascular events,
acute coronary syndrome, microvascular
complications, and cardiovascular surgery.
Based on our results, 44.2% of patients
achieved both goals in the 7–12 months
following the index date. Prior dual-goal
achievement, older age, use of lipid-lowering
medication, and prior diagnosis of ketoacidosis
(without coma) and hyperosmolarity are
associated with an increased likelihood of
dual-goal achievement. Conversely, factors
associated with a decreased likelihood of
dual-goal achievement include retinopathy,
neuropathy, congestive heart failure and prior
use of insulin.
Benefits of Dual- and Single-Goal
Achievements
The absence of cardiovascular benefits in
patients with early-stage type 2 diabetes who
achieved dual HbA1c–LDL-C control is
consistent with observations available in the
literature. In a previous study with a mean
follow-up of 5.3 years, an early intensive
multifactorial intervention (aimed at reducing
HbA1c, LDL-C, and blood pressure) in patients
with diabetes mellitus detected by screening
was not associated with any statistically
significant difference in the rate of
cardiovascular events and all-cause mortality,
compared with routine care, despite
significantly better improvements in HbA1c
and LDL-C levels in the intensive treatment
group [24]. However, in Steno-2, a randomized
study in patients with established diabetes
(mean disease duration: 6 years), multifactorial
treatment was associated with significantly
lower rates of cardiovascular disease and
microvascular complications after 7.8 years of
follow-up, compared with standard care [17],
and further 5.5 years of follow-up demonstrated
significant benefits on cardiovascular mortality
[18]. In both periods of the Steno-2 study,
multifactorial treatment resulted in a higher
proportion of patients who achieved HbA1c
levels \6.5% (48 mmol/mol) and in mean
LDL-C levels \100 mg/dL [17, 18]. Taken
together, data from our analysis and the
studies that assessed the effects of
multifactorial intervention [17, 18, 24] suggest
that cardiovascular benefits of dual-goal over
single-goal achievements in patients with type 2
diabetes may be observed over a long term.
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Table 2 Characteristics associated with dual-goal achievement
Covariate Odds ratio (95% CI)a P value
Demographics
Age 1.02 (1.01, 1.02) <.001
Male 0.90 (0.73, 1.13) .368
Caucasian 1.01 (0.93, 1.09) .855
Body mass index 1.00 (0.99, 1.01) .821
Index year
2005 vs. 2004 0.92 (0.81, 1.05) .203
2006 vs. 2004 1.08 (0.94, 1.23) .292
2007 vs. 2004 1.16 (1.01, 1.33) .033
2008 vs. 2004 1.19 (1.04, 1.37) .010
2009 vs. 2004 1.21 (1.03, 1.42) .021
Baseline goal achievement
Dual-goal vs. non-dual-goal 16.19 (14.92, 17.58) <.001
Diabetes-related complications
Microvascular complications
Retinopathy 0.67 (0.55, 0.82) .001
Nephropathy 1.04 (0.77, 1.39) .806
Neuropathy 0.85 (0.76, 0.97) .012
Macrovascular complications
Atherosclerosis, aneurysm, or embolism 1.25 (0.97, 1.60) .085
Peripheral vascular disease 0.93 (0.78, 1.12) .453
Cerebrovascular disease 1.02 (0.88, 1.19) .784
Coronary artery disease
Angina 0.93 (0.75, 1.16) .545
Myocardial infarction 0.77 (0.48, 1.23) .271
Other complications
Infectionb 0.94 (0.82, 1.07) .354
Ocular problemsc 1.09 (1.00, 1.19) .060
Ulcerationd 1.00 (0.71, 1.39) .982
Ketoacidosis (without coma) and hyperosmolarity 2.20 (1.18, 3.94) .010
Hypoglycemia 1.15 (0.90, 1.46) .254
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Table 2 continued
Covariate Odds ratio (95% CI)a P value
Comorbidities
Cardiovascular diseasee
Congestive heart failure 0.84 (0.70, 0.99) .043
Valvular heart disease 1.02 (0.76, 1.36) .920
Hypertension 1.12 (0.94, 1.34) .204
Other cardiovascular disease 1.08 (0.97, 1.20) .168
Hyperlipidemia 0.84 (0.70, 1.00) .051
Depression 1.05 (0.95, 1.15) .366
Renal disease 1.05 (0.88, 1.24) .593
Tobacco use 1.00 (0.89, 1.12) .949
Diabetic medications
Oral antidiabetic 1.06 (0.97, 1.15) .191
Insulin 0.70 (0.61, 0.81) <.001
Antihypertensive 0.94 (0.86, 1.04) .227
Lipid lowering 1.53 (1.39, 1.69) <.001
Surgical procedures
Lower extremity amputation 0.59 (0.22, 1.46) .265
Coronary artery bypass graft 1.22 (0.62, 2.38) .566
Percutaneous coronary intervention 0.98 (0.63, 1.54) .945
Resource utilization
Outpatient visit 1.06 (0.76, 1.49) .726
Urgent care visitf 1.04 (0.93, 1.18) .489
Charlson Comorbidity Index
1 B CCI\3 vs. CCI = 0 1.15 (1.03, 1.29) .012
CCI C 3 vs. CCI = 0 1.40 (1.08, 1.81) .012
Statistical signiﬁcance is indicated with bolded text
95% CI 95% conﬁdence interval, CCI Charlson Comorbidity Index
a Odds ratio[1 indicates a higher likelihood of dual-goal achievement (deﬁned as HbA1c\7% (53 mmol/mol) and
LDL-C\100 mg/dL). Goal achievement status was determined at 7–12 months following the index date; covariates were
measured in the 1-year period around the index date (i.e., 6 months before and 6 months after). Hosmer and Lemeshow
goodness-of-ﬁt test suggested that the model ﬁt well (P[ .05)
b Includes skin, urinary tract, and kidney infections
c Includes glaucoma, macular edema, retinal edema, vitreous hemorrhage, and blindness
d Includes foot ulcer, bone changes, amputation, and other ulcerations
e Excludes macrovascular complications
f Includes emergency room and inpatient visits
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Possibly, a follow-up time of 3.7 years in our
study was not sufficient to reveal such benefits.
The 1- and 3-year cumulative cardiovascular
event-free rates (96.4%, and 91.2%,
respectively) among patients with dual-goal
achievement in our study were similar to
patients with intensive treatment in the
Steno-2 study (approximately 97.8% and
87.5% by year 1 and 3, respectively) [18].
The observed cardiovascular benefits of
single-goal achievement (HbA1c or LDL-C)
versus no-goal achievement are also consistent
with literature [25–27].
Status and Characteristics Associated
with Dual-Goal Achievement
Given that, only 44.2% of patients achieved
both the HbA1c and LDL-C goals in the
7–12 month period following the index date,
our results suggest an unmet need in
controlling major risk factors for patients with
newly diagnosed diabetes. This is consistent
with available literature [2].
Our results also show that prior dual-goal
achievement, older age, and the use of
lipid-lowering drugs are associated with
dual-goal achievement. On the contrary,
insulin use and diabetes-related complications
such as neuropathy, retinopathy, and
congestive heart failure, which indicate a more
advanced phase of the disease, are identified as
characteristics associated with a decreased
likelihood of dual-goal achievement. These
results highlight the importance of timely
intervention and regular medical care in
achieving HbA1c and LDL-C goals.
These results are consistent with findings
from several other studies. Older age was
associated with the achievement of HbA1c
goal in a recent retrospective cohort study of
individuals with type 2 diabetes [28] and with
the achievement of simultaneous glycemic,
lipid, and blood pressure control in patients
with diabetes, hypercholesterolemia, and
hypertension [29]. In addition, a recently
presented conference proceeding of a
retrospective cohort study found that patients
with diabetes who attained HbA1c levels\7%
(53 mmol/mol) were generally older and less
likely to receive insulin than patients who had
not achieved HbA1c goal [30]. The Look AHEAD
study (ClinicalTrials.gov # NCT00017953)
suggested that insulin use and non-utilization
of lipid-lowering drugs was associated with a
failure to achieve all three goals (HbA1c, LDL-C,
and blood pressure) among overweight and
obese patients with diabetes [31]. Finally,
achievement of the LDL-C goal has been
directly associated with older age, and
inversely associated with baseline LDL-C [32].
Limitations and Strengths
Due to the retrospective observational design,
the analysis may have been affected by
unobserved differences that were not taken
into account in the model. Although we used
strict selection criteria, there is a possibility we
included some patients who were not truly
newly diagnosed with T2DM. Specifically, we
observed an unexpectedly high rate of insulin
use during the 6-month post-index period.
Patients who did not achieve either goal were
on average about 8 years younger and used 4
times more insulin than those who achieved
both goals (20.9% vs. 5.0%). It is possible that
some of these younger patients who were using
insulin were suffering from latent autoimmune
diabetes of adults instead of type 2 diabetes [33].
In addition, some important information was
not captured in the electronic medical records,
including disease severity, disease duration,
lifestyle modifications, and any potential (but
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unlikely) health care services that were provided
outside of the Veterans Affairs (VA) health
system. We did not look into the specific
information about alternative
cholesterol-lowering drugs and
antihypertensive drugs. Furthermore, the VA
database predominantly consists of male
patients, which may limit generalization of
findings. One of the major advantages of using
electronic records from VA health system is that
the lab values are recorded over time, allowing
for a longitudinal study design with a median
follow-up period of 3.7 years.
Similar studies in the general population,
designed to assess the effects of medication,
lifestyle changes, or triple-goal achievement
(HbA1c, LDL-C, and blood pressure) may
provide additional information. In addition,
analyses with longer follow-up times may
reveal benefits of dual- or triple-goal
achievements on cardiovascular outcomes that
were not observed in this study.
CONCLUSION
In US veterans with a newly recorded diagnosis
of type 2 diabetes, the main benefit of achieving
both HbA1c and LDL-C goals over achieving
only LDL-C goal appears to be a reduced rate of
microvascular complications. However, current
rates of dual-goal achievement are suboptimal.
Prior dual-goal achievement and use of
lipid-lowering drugs were both associated with
a higher rate of dual-goal achievement, which
highlights the importance of early intervention
and regular medical care.
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